
1. nat commun. 2019 sep 20;10(1):4300. doi: 10.1038/s41467-019-12256-9.

plasmodium vivax chloroquine resistance links pvcrt transcription genetic
cross.

sá jm(1), kaslow sr(1), moraes barros rr(1), brazeau nf(2), parobek cm(3), tao
d(4), salzman re(1), gibson tj(1), velmurugan s(5), krause ma(1), melendez-muniz 
v(1), kite wa(1), han pk(1), eastman rt(1), kim a(6), kessler eg(1), abebe y(5), 
james er(5), chakravarty s(5), orr-gonzalez s(7), lambert le(7), engels t(8),
thomas ml(8), fasinu ps(9), serre d(6), gwadz rw(1), walker l(9), deconti dk(10),
mu j(1), bailey ja(9)(11), sim bkl(5), hoffman sl(5), fay mp(12), dinglasan
rr(4)(13), juliano jj(2)(3)(14), wellems te(15).

author information: 
(1)laboratory malaria vector research, national institute allergy and
infectious diseases, national institutes health, bethesda, md, 20892, usa.
(2)department epidemiology, gillings school global public health,
university north carolina, chapel hill, nc, 27599, usa.
(3)curriculum genetics molecular biology, school medicine, university
of north carolina chapel hill, chapel hill, nc, 27599, usa.
(4)w harry feinstone department molecular microbiology immunology, johns
hopkins bloomberg school public health, baltimore, md, 21205, usa.
(5)sanaria inc., rockville, md, 20850, usa.
(6)institute genome sciences, university maryland school medicine,
baltimore, md, 21201, usa.
(7)laboratory malaria immunology vaccinology, national institute of
allergy infectious diseases, national institutes health, bethesda, md,
20892, usa.
(8)division veterinary resources, office research services, national
institutes health, bethesda, md, 20892, usa.
(9)department pharmaceutical sciences, college pharmacy health
sciences, campbell university, buies creek, nc, 27506, usa.
(10)program bioinformatics integrative biology, university of
massachusetts medical school, worcester, ma, 01655, usa.
(11)division transfusion medicine, department medicine, university of
massachusetts medical school, worcester, ma, 01655, usa.
(12)biostatistics research branch, national institute allergy infectious
diseases, national institutes health, rockville, md, 20852, usa.
(13)emerging pathogens institute, department infectious diseases & immunology,
college veterinary medicine, university florida, gainesville, fl, 32611,
usa.
(14)division infectious diseases, school medicine, university north
carolina chapel hill, chapel hill, nc, 27599, usa.
(15)laboratory malaria vector research, national institute allergy 
infectious diseases, national institutes health, bethesda, md, 20892, usa.
twellems@niaid.nih.gov.

mainstay treatment plasmodium vivax malaria long relied chloroquine
(cq) blood-stage parasites plus primaquine dormant liver-stage
forms (hypnozoites), however drug resistance confronts regimen threatens
malaria control programs. understanding basis p. vivax chloroquine
resistance (cqr) inform drug discovery malaria control. we
investigate genetics p. vivax cqr cross parasites differing in
drug response. gametocytogenesis, mosquito infection, progeny production 
performed mixed parasite populations nonhuman primates, methods p.
vivax cloning vitro cultivation remain unavailable. linkage mapping of
progeny surviving >15 mg/kg cq identifies 76 kb region chromosome 1
including pvcrt, ortholog plasmodium falciparum cqr transporter gene.
transcriptional analysis supports upregulated pvcrt expression mechanism 
cqr.

doi: 10.1038/s41467-019-12256-9 
pmcid: pmc6754410
pmid: 31541097  [indexed medline]

